Mounjaro: A Breakthrough in Weight Loss Treatment

Mounjaro (tirzepatide) is a GLP-1 receptor agonist approved in the UK for weight management in adults with obesity (BMI ≥30) or those with a BMI ≥27 and weight-related health conditions. It works by regulating appetite and slowing gastric emptying, leading to reduced food intake and significant weight loss. In clinical trials, patients using Mounjaro weight loss of up to 22.5%. The medication is administered via a weekly injection, with doses ranging from 2.5mg to 15mg. Mounjaro is expected to be available through the NHS starting in April 2025, with private clinics offering it now. It's important to use Mounjaro alongside a reduced-calorie diet and increased physical activity for optimal results.